Elacestrant May Improve Outcomes for Patients Whose Metastatic Breast Cancers Progressed on Prior Endocrine Therapy
Elacestrant is the first oral selective estrogen receptor degrader to show clinical benefit over standard of care in a...
Elacestrant is the first oral selective estrogen receptor degrader to show clinical benefit over standard of care in a...
Imaging mass cytometry was feasible in a large clinical trial of atezolizumab in combination with chemotherapy SAN ANTONIO –...
The ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) was highly predictive of the benefits of targeted therapies...
Next-generation sequencing for minimal residual disease was highly sensitive and more accurate than flow cytometry and monitoring of B-cell...
PHILADELPHIA – Today, the American Association for Cancer Research (AACR) and Pelotonia announced the establishment of a new grants...
PHILADELPHIA – A diet involving short-term, severe calorie restriction was safe, feasible, and resulted in a decrease of blood...
AACR expresses appreciation to Janet Woodcock, MD, for her excellent stewardship as FDA’s Acting Commissioner for the past 10...
SAN ANTONIO – The San Antonio Breast Cancer Symposium (SABCS) and the American Association for Cancer Research (AACR), an...
Recognition to occur at SITC Annual Meeting in Washington, D.C. PHILADELPHIA – The American Association for Cancer Research (AACR)...
PHILADELPHIA – Patients with advanced renal cell carcinoma who received the checkpoint inhibitor combination nivolumab (Opdivo) plus ipilimumab (Yervoy)...